Article

PAP 2023: Gwen Cooper Discusses Improving Access to Mental Health Presentation at Access PAP 2023

Accessia Health CEO provides a synopsis of her session.

In an interview with Pharma Commerce Editor, Nicholas Saraceno, Gwen Cooper, president & CEO, Accessia Health, provides a detailed summary of her discussion.

Newsletter

Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.

Subscribe Now!
Related Videos
Related Content
Asembia 2025: What Pharma Leaders Must Know About Tariffs, Supply Chains, and Policy Changes
May 1st 2025

Asembia 2025: What Pharma Leaders Must Know About Tariffs, Supply Chains, and Policy Changes

Don Tracy, Associate Editor
The Zensights Federated Healthcare Advisory Panel explores how shifting global dynamics are reshaping access and strategic planning across the healthcare system.
Asembia 2025: The Cost of Care for Patients
May 1st 2025

Asembia 2025: The Cost of Care for Patients

Nicholas Saraceno, Editor
Subject matter experts share the challenges that patients face in terms of medication affordability, along with the role that specialty pharmacies can play in helping to tackle these issues.
Asembia 2025: Rethinking the Drug Distribution Process
April 30th 2025

Asembia 2025: Rethinking the Drug Distribution Process

Nicholas Saraceno, Editor
A panel of experts examines how stakeholders can support strategies that improve patient outcomes, while also navigating various distribution models.
Asembia 2025: Understanding the Inflation Reduction Act
April 30th 2025

Asembia 2025: Understanding the Inflation Reduction Act

Nicholas Saraceno, Editor
A seminar shares key observations and learnings from the first round of direct price negotiations.
Asembia 2025: Rare Disease Therapies Drive Shift in Drug Development Focus
April 30th 2025

Asembia 2025: Rare Disease Therapies Drive Shift in Drug Development Focus

Don Tracy, Associate Editor
Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar gaps, reimbursement pressure from GLP-1s, and persistent access challenges.
Asembia 2025: A General Landscape of the Pharmaceutical Industry
April 29th 2025

Asembia 2025: A General Landscape of the Pharmaceutical Industry

Nicholas Saraceno, Editor
IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.
© 2025 MJH Life Sciences

All rights reserved.